Feed CKDXF
CK
Ceryvyn Therapeutics Ltd CKDXF · OTC
$0.01 +0.00% (+$0.00)
Depth
- Market cap
- $14.6M
- Enterprise value
- -$6.13M
- P/E
- 0.1x
- Forward P/E
- -
- PEG
- -
- P/S
- 21,182.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -40.4%
- Gross margin
- 0.0%
- Net margin
- 33,082,300.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.51
- Free float
- 85.4%
Sector
Healthcare
Industry
Biotechnology
CEO
Jeremy Max Levin Ba Zoology Dphil Mb Bchir
Employees
33
Headquarters
Hawthorn East
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: Revenue fell by 81% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 33,082,300 USD is left as net profit.
- What to watch: It reports a profit, yet spends more cash than it brings in.
Financial health
Can it carry its debt?
- What speaks for it: It has no debt and holds $20.8M in cash.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number